NCT03748641 2026-04-13MAGNITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting765 enrolled 16 charts 2 FDA
NCT04497844 2026-04-13AMPLITUDEJanssen Research & Development, LLCPhase 3 Active not recruiting696 enrolled 15 charts 3 FDA
NCT02166463 2026-03-17Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaNational Cancer Institute (NCI)Phase 3 Active not recruiting600 enrolled 14 charts 1 FDA